Glaxosmithkline
GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
DitchCarbon Score
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glaxosmithkline's reported carbon emissions
In 2024, GlaxoSmithKline (GSK) reported total carbon emissions of approximately 92,000 kg CO2e for Scope 1 and 2 in Great Britain. Globally, their emissions included about 521,000,000 kg CO2e for Scope 1 and approximately 44,000,000 kg CO2e for Scope 2 (market-based). In 2023, GSK's global emissions were significantly higher, with Scope 1 at about 581,000,000 kg CO2e, Scope 2 (market-based) at approximately 64,000,000 kg CO2e, and Scope 3 emissions reaching about 8,983,000 kg CO2e. GSK has set ambitious climate commitments, aiming for net zero emissions across all operations (Scope 1 and 2) by 2030. They achieved a 15% reduction in Scope 1 and 2 emissions from 2020 to 2021. For the longer term, GSK targets a 90% reduction in absolute emissions across all scopes by 2045, using 2020 as the baseline. Additionally, they have committed to reducing Scope 3 emissions by 80% by 2030. These targets align with GSK's broader sustainability strategy, which includes investments in high-quality nature-based solutions to offset remaining emissions. GSK's commitment to climate action is further reinforced by their participation in the Science Based Targets initiative (SBTi), ensuring their goals are consistent with the latest climate science.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000 | 0,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
